Witnessing the stock’s movement on the chart, on Wednesday, AMGEN Inc (NASDAQ: AMGN) set off with pace as it heaved 1.18% to $297.32, before settling in for the price of $293.85 at the close. Taking a more long-term approach, AMGN posted a 52-week range of $253.30-$335.88.
The Healthcare sector firm’s twelve-monthly sales growth has been -10.10% for the last half of the decade. Meanwhile, its Annual Earning per share during the time was -10.10%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 6.31%. This publicly-traded company’s shares outstanding now amounts to $538.30 million, simultaneously with a float of $537.30 million. The organization now has a market capitalization sitting at $160.07 billion.
AMGEN Inc (AMGN) Ownership Facts and Figures
Nothing is more important than checking the behaviour of major investors towards the stock of the Drug Manufacturers – General industry. AMGEN Inc’s current insider ownership accounts for 0.20%, in contrast to 82.03% institutional ownership. According to the most recent insider trade that took place on Aug 20 ’25, this organization’s SVP & CCO sold 1,267 shares at the rate of 296.99, making the entire transaction reach 376,280 in total value, affecting insider ownership by 7,209.
AMGEN Inc (AMGN) Earnings and Revenue Records
Wall Street market experts anticipate that the next fiscal year will bring earnings of 5.09 per share during the current fiscal year.
AMGEN Inc’s EPS increase for this current 12-month fiscal period is 6.31% and is forecasted to reach 21.61 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will increase by 4.18% through the next 5 years, which can be compared against the -10.10% growth it accomplished over the previous five years trading on the market.
AMGEN Inc (NASDAQ: AMGN) Trading Performance Indicators
Let’s observe the current performance indicators for AMGEN Inc (AMGN). It’s Quick Ratio in the last reported quarter now stands at 0.98. Alongside those numbers, its PE Ratio stands at $24.32, and its Beta score is 0.43. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 4.60. Similarly, its price to free cash flow for trailing twelve months is now 15.09.
In the same vein, AMGN’s Diluted EPS (Earnings per Share) trailing twelve months is recorded 12.22, a figure that is expected to reach 5.04 in the next quarter, and analysts are predicting that it will be 21.61 at the market close of one year from today.
